Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

244.26 USD -11.04 (-4.32%)
Official Closing Price Updated: 7:56 PM EDT, Oct 28, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix — Fundamental Analysis, Key Performance
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kimball Electronics, Inc.... 
From GlobeNewswire News Releases
This Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen
From PR Newswire
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively 
From Business Wire News Releases
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
BIOGEN TO REPORT FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS ON JANUARY 25, 2018- UPDATED CALL TIMING 
From Business Wire News Releases
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint 
From Business Wire News Releases
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018 
From Business Wire News Releases
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY 
From Business Wire News Releases
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen
From PR Newswire
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference 
From Business Wire News Releases
Biogen Appoints Mark Hernon as SVP, Chief Information Officer
Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4. 
From Business Wire News Releases
Recent Analysis Shows Aflac, Biogen, Oasis Petroleum, Twilio, Neothetics, and McDonald's Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aflac Incorporated... 
From GlobeNewswire News Releases
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral,... 
From Business Wire News Releases
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral,... 
From Business Wire News Releases
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December 11, 2017. 
From Business Wire News Releases
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Biogen to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference 
From Business Wire News Releases
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
From ACN Newswire
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation. 
From Business Wire News Releases
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
BIOGEN PRESENTS NEW DATA FROM LONG-TERM EXTENSION OF PHASE 1B STUDY OF INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB 
From Business Wire News Releases
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy 
From Business Wire News Releases
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference 
From Business Wire News Releases
Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Biogen and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® (nusinersen). 
From Business Wire News Releases
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis 
From Business Wire News Releases
Biogen Reports Quarterly Revenues of $3.1 Billion
Biogen Reports Quarterly Revenues of $3.1 Billion 
From Business Wire News Releases
Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG
BIOGEN INCREASES PROFIT POTENTIAL ON INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB THROUGH AMENDED AGREEMENT WITH NEURIMMUNE HOLDING AG 
From Business Wire News Releases
Research Report Identifies Sherwin-Williams, Charter Communications, Biogen, C. R. Bard, Mohawk Industries, and Humana Inc. with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Sherwin-Williams... 
From GlobeNewswire News Releases
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today... 
From Business Wire News Releases
Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle MS at the seventh joint meeting of ECTRIMS/ACTRIMS. 
From Business Wire News Releases
Align Biopharma Introduces New Technology Standard to Enable Single Sign-on for Healthcare Providers
Align Biopharma finalized an identity management technology standard that will make it easier for HCPs to access online content across life sciences. 
From Business Wire News Releases
Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.